Answers are grounded in this paper and cite their sources.
Background Guselkumab, an IL‐23 inhibitor, improved disease activity through five years in clinical trials of patients with moderate to severe plaque psoriasis. However, real‐world long‐term effectiveness of persistent use of guselkumab is not well characterized. Objective To evaluate the 2‐year effectiveness of persistent guselkumab therapy among US and Canadian real‐world patients with moderate to severe plaque psoriasis in the CorEvitas Psoriasis Registry. Methods Adult patients enrolled in the CorEvitas Psoriasis Registry between July 2017 and September 2021 with moderate to severe plaque psoriasis (body surface area [BSA] ≥ 3% and Investigator’s Global Assessment [IGA] ≥ 3) at index visit); moderate to severe disease activity; 2 years of persistent guselkumab therapy after index date; and a clinical visit 18–24 months postinitiation of guselkumab. Results were summarized by descriptive statistics. Results A total of 183 patients were included, with a mean duration of guselkumab use of 20.5 months (SD = 1.9). Most patients were White ( n = 147; 80%) and were male ( n = 108; 59%), with a mean age of 50 years and a mean disease duration of 16 years; 58% ( n = 106) were biologic‐experienced. For the overall cohort, most patients achieved clinically meaningful skin clearance: IGA 0/1 ( n = 126; 69% [95% confidence interval (CI): 62%, 76%]), PASI 90 ( n = 105; 58% [50%, 65%]), and National Psoriasis Foundation target response (BSA ≤ 1%) ( n = 122; 67% [60%, 74%]). Patients reported meaningful improvement in VAS scores for fatigue (mean change: −14.4 [SD = 29.7]), itch (−41.3 [SD = 34.3]), skin pain (−28.1 [SD = 34.3]), and patient global assessment (−35.9 [SD = 34.9]). Over two‐thirds achieved DLQI 0/1 ( n = 124/180, 69%). Improvements in clinically meaningful outcomes were reported for both biologic‐experienced and biologic‐naïve groups. Conclusions The majority of patients with moderate to severe plaque psoriasis who were persistent on guselkumab therapy for 2 years achieved clinically meaningful and durable improvements in skin clearance, disease activity, and PROs regardless of prior biologic experience.
No takes yet. Share an insight, caveat, or question.
Strober et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: